A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age19+
SponsorImmuneOncia Therapeutics Inc.
About this trial
The goal of this clinical trial is to determine the efficacy of IMC-001 in metastatic or locally advanced TMB-H solid tumor patients.
Eligibility criteria
Qualifiers
Documented TMB-H:≥ 16 mut/Mb, determined by the TruSightTM Oncology 500 NGS panel or OncomineTM Comprehensive Assay Plus
Histologically or cytologically proven metastatic or locally advanced solid tumors.The participant must have at least one measurable tumor lesion per RECIST 1.1.
Investigator has confirmation that participant's tumor tissue is available to be submitted to a central pathology laboratory.
Adult age(as defined by respective country)
Disqualifiers
Previously treated with an anti-PD-L1 or anti-PD-1 antibody
Known presence of symptomatic CNS metastases
Any active autoimmune disease or a documented history of autoimmune disease
Apparent active and known viral infection with HIV, hepatitis B virus or hepatitis C virus
Trial design
Treatments tested in this trial
- IMC-001
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov